CLASS ACTION UPDATE for EVA, EIGR and CURV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / January 3, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EVA Shareholders Click Here: https://www.zlk.com/pslra-1/enviva-class-action-submission-form?prid=35285&wire=1
EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=35285&wire=1
CURV Shareholders Click Here: https://www.zlk.com/pslra-1/torrid-holdings-class-action-submission-form?prid=35285&wire=1
* ADDITIONAL INFORMATION BELOW *
Enviva Inc. (NYSE:EVA)
EVA Lawsuit on behalf of: investors who purchased February 21, 2019 - October 11, 2022
Lead Plaintiff Deadline: January 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enviva-class-action-submission-form?prid=35285&wire=1
According to the filed complaint, during the class period, Enviva Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Enviva had misrepresented the environmental sustainability of its wood pellet production and procurement; (ii) Enviva had similarly overstated the true measure of cash flow generated by the Company's platform; (iii) accordingly, Enviva had misrepresented its business model and the Company's ability to achieve the level of growth that defendants had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 - October 4, 2022
Lead Plaintiff Deadline: January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=35285&wire=1
According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Torrid Holdings Inc. (NYSE: CURV)
This lawsuit is on behalf of all persons who purchased Torrid common stock in or traceable to the Company's July 2021 initial public offering.
Lead Plaintiff Deadline : January 17, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/torrid-holdings-class-action-submission-form?prid=35285&wire=1
According to the filed complaint, (i) in the first half of 2021, Torrid had experienced a temporary surge in demand as a result of changed consumer behaviors in response to the COVID-19 pandemic and government stimulus and that such ephemeral demand trends had dissipated and were not internally projected to continue following the initial public offering ("IPO"); (ii) Torrid was suffering from severe supply chain disruptions caused by the emergence of the Delta variant of COVID-19, which had first emerged in May 2021; (iii) Torrid was running materially below historical inventory levels as a result of supply chain disruptions; (iv) as a result, Torrid did not have sufficient inventory to meet expected consumer demand for its fiscal third quarter of 2021; (v) as a result, late inventory arrival had materially impaired the Company from effectively matching consumer buying trends, creating an undisclosed risk of increased markdowns and promotional activities necessary to sell undesirable inventory; (vi) Torrid's Chief Financial Office planned to retire shortly after the IPO; and (vii) as a result of the above, representations made in the Company's registration statement regarding Torrid's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, financial results, and trajectory of the Company at the time of the IPO, and were materially false and misleading and lacked a reasonable factual basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: